Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on September 26, 2005
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyi155
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/10/572    most recent
hyi155v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rastogi, M.
Right arrow Articles by Bhatt, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rastogi, M.
Right arrow Articles by Bhatt, M. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Foundation for Promotion of Cancer Research
Received May 10, 2005
Accepted July 18, 2005

Original Article

Mitomycin and Fluorouracil in Combination with Concomitant Radiotherapy: A Potentially Curable Approach for Locally Advanced Head and Neck Squamous Cell Carcinoma

Madhup Rastogi 1*, Madhu Srivastava 1, Kundan S. Chufal 2, M. C. Pant 1, Kirti Srivastava 1, and Madanlal B. Bhatt 1

1 Department of Radiotherapy, King George's Medical University, Lucknow, Uttar Pradesh, India
2 Department of Oncology, Batra Hospital and Medical Research Center, New Delhi, India

* To whom correspondence should be addressed.
Madhup Rastogi, E-mail: drmadhup1{at}rediffmail.com


  Abstract

Objective: The purpose of this study was to evaluate the efficacy of radiotherapy and concurrent mitomycin-C (MC) plus 5-fluorouracil (5FU) infusion in locally advanced squamous cell carcinoma of head and neck (SCCHN).

Methods: Sixty-nine patients with SCCHN (6 Stage III and 63 Stage IV patients) were treated with external beam radiotherapy (70 Gy) and simultaneous intravenous chemotherapy with 5FU (600 mg/m2/day, Days 1-5) and MC (10 mg/m2, Days 5 and 36).

Results: After a mean follow-up of 28.5 months, 59.4% of patients were alive without disease. Complete response was seen in 76.8% of patients. The 3 years overall survival, locoregional relapse-free survival and disease-free survival was 62.3, 89.8 and 49.5%, respectively. Treatment was well tolerated (Grade III mucositis in 43.5% and Grade II leukopenia in 5.8%).

Conclusions: This concurrent chemoradiotherapy regimen offers a curative option for our patients where primary and nodal disease is fairly large resulting in hypoxic radioresistant tumors.

Keywords: head and neck cancer; radiotherapy; concurrent; mitomycin-C; hemoglobin.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K. S. Chufal, M. Rastogi, M. Srivastava, M. C. Pant, M. L. B. Bhatt, and K. Srivastava
Analysis of Prognostic Variables among Patients with Locally Advanced Head and Neck Cancer Treated with Late Chemo-Intensification Protocol: Impact of Nodal Density and Total Tumor Volume
Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 537 - 546.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.